Astronin — Salmon Calcitonin

Anti-resorptive hormone that inhibits osteoclastic bone resorption. Stabilizes bone turnover, reduces acute vertebral fracture pain, and improves calcium homeostasis. For postmenopausal osteoporosis and vertebral compression fractures.

Masden — Denosumab

RANKL Inhibitor (IgG2). Blocks RANKL–RANK interaction, preventing osteoclast formation. Reduces vertebral fractures by up to 68% and hip fractures by 40% (FREEDOM study). No renal dose adjustments required.

Mechanism

Blocks RANKL–RANK interaction, preventing formation, function, and survival of osteoclasts. Decreases cortical & trabecular bone resorption. Increases BMD at hip, lumbar spine, and femoral neck. Indicated for postmenopausal osteoporosis, osteoporosis in men, steroid-induced osteoporosis, and high-fracture-risk patients.

Axiatide — Teriparatide

Anabolic bone-forming agent (PTH 1-34). Stimulates osteoblast proliferation and builds new bone. Increases lumbar spine BMD by 9–13%, reduces vertebral fractures by 65% and nonvertebral fractures by 53%.

Mechanism

Intermittent PTH (1-34) activates cAMP/PKA pathway, promotes osteoblast recruitment & reduces apoptosis. Enhances trabecular connectivity and bone microarchitecture. Ideal for severe osteoporosis with multiple fractures or ineffective response to antiresorptives. Also indicated for osteoporosis in men and GIOP.

TENDCART

TENDCART's bioactive matrix technology holds particular promise in osteoporosis management, where the compromised bone-cartilage interface presents unique therapeutic challenges. Its scaffold components are designed to support structural repair at the subchondral level — addressing the root cause of joint degeneration in osteoporotic bone.

By promoting integrated bone and cartilage repair, TENDCART aims to offer osteoporosis patients a treatment option that addresses joint degeneration at its structural source, complementing systemic antiresorptive therapies.

The Future of Bone-Cartilage Repair

Preclinical models of osteoporosis-related OA show TENDCART promoting mineralisation of the tidemark zone and restoration of the osteochondral unit — a unique mechanism of action with significant implications for osteoporosis-driven joint disease.

Masgaba-NT

Class: Neuropathic pain modulator / Co-analgesic

Mechanism of Action

Gabapentin: Reduces presynaptic calcium influx, decreases release of glutamate and substance P, dampens ectopic neuronal firing.

Nortriptyline: Enhances descending inhibitory pain circuits, exhibits antihyperalgesic activity, modulates central sensitization.

Syno One Plus

For patients requiring faster and more complete pain control, Syno One Plus combines the sustained pain-modulating properties of viscosupplementation with the rapid analgesic and anti-inflammatory action of a targeted corticosteroid component — providing immediate relief alongside long-term joint protection.

This formulation is ideally positioned within step-up pain management protocols, serving patients who have experienced partial but insufficient response to either single-agent analgesia or standard viscosupplementation.

Optimising Pain Outcomes

The complementary onset profiles of the two active components — immediate corticosteroid action within hours and progressive HA benefit over weeks — deliver a pain control curve uniquely suited to the variable, episodic nature of chronic joint pain.

Syno One XL

Hip and shoulder pain are among the most functionally debilitating pain presentations in musculoskeletal practice. Syno One XL's extended-volume formulation ensures complete analgesic coverage of these large joint spaces, addressing pain arising from the full articular surface rather than only the area reached by standard injection volumes.

For patients with large-joint pain that has been refractory to oral and topical analgesics, Syno One XL offers a targeted, evidence-based intra-articular option with a compelling safety and efficacy profile.

Large Joint Pain: A Different Challenge

Undertreated hip and shoulder pain drives significant disability and opioid escalation. Syno One XL's adequate joint coverage directly addresses the inadequate distribution problem that limits analgesic outcomes with standard-volume formulations in large joints.

TENDCART

Unlike conventional analgesics that manage pain symptoms, TENDCART targets the structural tissue damage that drives persistent pain in cartilage and tendon disorders. By promoting genuine tissue repair, TENDCART aims to offer durable pain relief that reduces and potentially eliminates the need for ongoing symptomatic treatments.

This disease-modifying approach to pain management represents a paradigm shift — addressing the underlying pathology rather than masking its symptoms, with early data suggesting sustained pain reduction well beyond treatment completion.

The Disease-Modifying Advantage

For patients trapped in cycles of escalating analgesic use, TENDCART's regenerative mechanism offers a credible exit pathway — restoring tissue integrity and eliminating the structural pain source rather than suppressing the pain signal alone.

MJAK-T

Class: JAK Inhibitor (JAK1 & JAK3 predominant) | Oral targeted synthetic DMARD(tsDMARD)

Mechanism

Inhibits JAK1/JAK3, suppresses STAT dependent transcription. Reduces IL-2, IL-4, IL-6, IL-7, IL-15, IL-21 signalling. Decreases T-cell activation and rapidly reduces synovial inflammation.

Syno One Plus

Autoimmune joint flares are a defining feature of conditions like RA and PsA, causing acute inflammation that erodes joint integrity and severely impacts patient quality of life. Syno One Plus delivers targeted intra-articular corticosteroid therapy for flare control alongside lasting HA-mediated joint protection — a clinically powerful combination in autoimmune arthropathy management.

Particularly valuable as a bridge therapy during biologic treatment transitions or step-up DMARD changes, Syno One Plus controls localised joint inflammation while systemic agents reach therapeutic effect.

Bridging Therapy in Autoimmune Disease

When systemic therapy changes leave patients temporarily under-protected, Syno One Plus provides reliable local flare control and joint preservation — maintaining patient function and wellbeing through the treatment transition window.

Syno One XL

Systemic autoimmune conditions such as RA and AS frequently affect large joints including the hip, shoulder, and sacroiliac joint, where standard injection volumes are inadequate to provide full therapeutic coverage. Syno One XL ensures complete synovial treatment of these larger affected joint compartments.

For autoimmune patients with large-joint involvement refractory to systemic therapy alone, Syno One XL provides a targeted intra-articular option that complements biologic treatment without adding systemic immunosuppressive burden.

Large Joint Autoimmune Disease

In conditions like AS and RA where hip involvement drives significant disability, Syno One XL's validated large-joint efficacy offers a meaningful addition to treatment strategies that may otherwise have limited intra-articular options.

TENDCART

Autoimmune arthropathies are characterised by progressive, immune-mediated cartilage and connective tissue destruction that current systemic therapies slow but cannot reverse. TENDCART's regenerative bioactive matrix technology is specifically designed to address this irreversible structural damage — the critical unmet need in long-term autoimmune joint management.

By combining structural repair capability with localised anti-inflammatory activity, TENDCART could offer autoimmune patients the first genuine opportunity to recover, rather than merely preserve, joint function in the biologic era.

Repairing Autoimmune Joint Damage

Even with optimal systemic disease control, cartilage lost to years of autoimmune inflammation cannot be recovered by current therapies. TENDCART's regenerative mechanism opens a new therapeutic dimension in autoimmune joint care.